New genetic clues linked to IgA nephropathy and kidney disease risk
Researchers from Columbia University have identified a set of 16 regions in the human genome that are associated with the most common form of glomerulonephritis, a kidney condition where the immune system damages the filtering units known as glomeruli. The findings appear in Nature Genetics and mark a significant step toward understanding why some people develop this disease.
Glomeruli serve a critical role in filtering the liquid portion of blood to form primary urine. In IgA nephropathy, immune system activity appears to harm these tiny structures, potentially leading to kidney failure. Across the world, this disease contributes to roughly 10 to 50 percent of glomerulonephritis cases, depending on the population studied and the diagnostic criteria used.
In a large-scale analysis that included nearly 40,000 participants, scientists pinpointed 16 genomic regions that correlate with immunoglobulin A (IgA) nephropathy. The data indicate that the root cause of the disease lies outside the kidneys and is driven by immune system processes. This shifts some focus from kidney-specific factors to systemic immune mechanisms in disease development and progression.
Despite its prevalence, diagnosing IgA nephropathy remains challenging because confirmation typically requires a kidney biopsy, which is invasive and carries risk. The study brought together close to 200 researchers from about 100 institutions over a decade, who contributed samples from patients with biopsy-proven IgA nephropathy. The collaboration culminated in a robust dataset shared with scientists at Columbia University to enable detailed genetic analysis.
The research supports a central hypothesis: the immune system actively shapes the course of IgA nephropathy. This insight opens avenues for therapies that target the disease’s underlying causes rather than only addressing symptoms. In early work, researchers have identified two drug candidates with potential to modify disease pathways, and they have outlined a genetic risk profile that could help clinicians identify patients at greatest risk of progressing to kidney failure.
These advances emphasize the possibility of translating genetic discoveries into practical clinical tools. By combining genome-wide association data with immune biology, scientists aim to refine risk prediction, guide treatment decisions, and accelerate the development of targeted therapies. The collaboration highlights how large-scale data sharing and cross-institutional effort can turn complex genetic signals into meaningful therapeutic strategies for IgA nephropathy, potentially improving outcomes for patients in North America and beyond. [Cite: Nature Genetics study on IgA nephropathy, collaborative report from multiple centers, including Columbia University, 202X]
The final takeaway is clear: IgA nephropathy is a disease where the immune system plays a central role, and the kidney damage observed in patients reflects systemic immune activity rather than kidney-intrinsic problems alone. As researchers continue to map genetic risk factors and test promising drugs, there is cautious optimism about better prevention, earlier diagnosis, and more effective treatments that address the root immune causes of the condition.
ancient scientists to solveWhich drug can increase the risk of fatty liver disease?